Table of Contents - WOC 2012

WOC2012 Abstract Book
FP-RET-TH 41 (10)
Parsplana Vitrectomy and Intravitreal Phacoemulsification for
Removal of the Dropped Nucleus
Ghasemi Falavarjani Khalil (1) , Hashemi Masih (1) , Modarres Mehdi (1) ,
Jalilifazel Ali (1)
1. Eye Research Center, Rassoul Akram Hospital, Tehran University of Medical
Science
Purpose: To evaluate the outcomes of parsplana vitrectomy (PPV) and
intravitreal phacoemulsification in patients with dropped nucleus after cataract
surgery.
Methods: In this retrospective case series, charts of patients who underwent
parsplana vitrectomy and intravitreal phacoemulsification for removal of
dislocated nucleus/lens fragments were reviewed. After a standard vitrectomy,
a conventional phaco probe with a shortened sleeve was used for grasping
and emulsification of the nucleus fragments in mid\anterior vitreous cavity.
Pre- and postoperative visual acuity and intraoperative and postoperative
complications were recorded.
Results: Twenty two patients with a mean age of 71.1 ±8.2 years were studied.
The mean interval between cataract surgery and PPV was 26.6 ±36.5 days
(range: 0-120). Patients were followed for a mean of 105.5 ±57.5 days.
Preoperative best corrected visual acuity of 2.4 ±0.6 LogMAR increased to
1.4 ±0.6 at final visit (P=3 Snellen›s lines
occurred in 7 eyes.
Conclusion: Radial micro-retinotomies through the hole edge and
endotamponade helps anatomic closure and improvement of vision in patients
with persistent or recurrent macular holes.
Hot Topics- New Evidence for Neuroprotection in Glaucoma
Thu 16 Feb 16:30 - 18:00 Hall 11
IS-GLA-TH 42 (1)
Imaging Retinal Ganglion Cell Injury and Death
Cordeiro Francesca
1. UCL Institute of Ophthalmology and Western Eye Hospital London
Objective: To provide a review of current & future imaging technologies and
their application to neuroprotection.
Synopsis: The RGC the key cell implicated in glaucoma, and any successful
therapy for this disease should ultimately prevent RGC death and vision loss.
Imaging technologies have thrown new light on to in vivo RGC events. This
lecture will review some of these techniques, including DARC, RGC fluorescent
labeling and high resolution imaging and their application to neuroprotection.
66
IS-GLA-TH 42 (2)
CNS Degeneration in Glaucoma: Opportunities and Challenges
Gupta Neeru
1. University of Toronto/St. Michael›s Hospital
Glaucoma is a neurodegenerative disease of the visual system. In addition to
the loss of retinal ganglion cells in the eye, there is injury to visual pathways of
the brain. Compelling evidence suggests that in addition to lowering intraocular
pressure, targeting central visual system degeneration is an opportunity to
slow disease progression and prevent vision loss in glaucoma.
IS-GLA-TH 42 (3)
Non-IOP Lowering Treatment in Glaucoma
Mozaffarieh Maneli
1. University of Basel
Increased intraocular pressure (IOP) is a major risk factor for glaucomatous
damage and reducing IOP improves prognosis. Nevertheless, there is little
doubt that other risk factors besides IOP are involved. Better knowledge of
the pathogenesis has opened up new therapeutical approaches. Whilst most
of these new avenues of treatment are still in the experimental phase, others
are already used by some physicians. Blood pressure dips can be avoided
by intake of salt or fludrocortisone. Vascular regulation can be improved
locally by carbonic anhydrase inhibitors, systemically with magnesium or with
low doses of calcium channel blockers. Experimentally, glaucomatous optic
neuropathy (GON) can be prevented by inhibition of astrocyte activation, either
by blockage of epidermal growth factor receptor, by counteracting Endothelin
or by nitric oxide-2 synthase inhibition. Reduction of oxidative stress especially
at the level of mitochondria also seems to be protective.
IS-GLA-TH 42 (4)
Autoimmune Mechanisms in Glaucoma
Grus Franz
The analysis of the complex autoantibody profiles against ocular antigens
revealed up-regulations, but also consistently significant down-regulations
of immunoreactivities against ocular antigens in glaucoma patients. They
can be causative to the disease, but some of them could also develop as a
consequence of the disease (epiphenomenon). These complex changes in
natural autoimmunity and the possible loss of protective functions in glaucoma
patients could lead to innovative new therapeutic immunomodulatory strategies
and to antibody biomarker for early detection.
IS-GLA-TH 42 (5)
Gene Transfer for Neuroprotection in Glaucoma
Borras Terete
1. Department of Ophthalmology, University of North Carolina at Chapel Hill
During this presentation I will summarize for you the latest advances of gene
therapy of glaucoma. In particular, I will focus on the protection of the retinal
ganglion cells (RGC) by the administration of safe Adeno-associated viral
vectors (AAV) carrying transgenes that confer a defense against the insult
of elevated intraocular pressure. I will discuss, in an easy to follow manner,
current animal glaucoma models available, second generation vectors and the
possibility to regulate gene delivery by inserting specific DNA elements in the
transgene.
Keratoconus and Refractive Surgery
Thu 16 Feb 16:30 - 18:00 Hall 1
IS-REF-TH 43 (1)
Placido-based Topographic Imaging for Screening Keratoconus
Klyce Stephen
1. Mount Sinai School of Medicine
The presence of keratoconus places patients at extremely high risk for the
development of keratoectasia should they undergo refractive surgery. Sensitive
and accurate screening for keratoconus depends upon Placido corneal
topography. This talk will review the reasons for stressing the use of Placido
topography rather than slit-based corneal tomography and will summarize
ways to optimize the recognition of those patients at risk.